How are treatments for myelodysplastic syndromes (MDS) selected?

Updated: Nov 04, 2019
  • Author: Matthew C Foster, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Treatment recommendations for myelodysplastic syndromes (MDS) are based on a patient’s  Revised International Prognostic Scoring System score in addition to evaluation of a patient’s performance status. Currently, only a few US Food and Drug Administration (FDA)–approved therapies for MDS are available, including hypomethylating agents such as azacitidine and decitabine, iron chelators such as deferasirox, and lenalidomide. [1] Special considerations and supportive care are also described below. [2]

See Myelodysplastic Syndromes: Classification, Features, Diagnosis, and Treatment Options, a Critical Images slideshow, to help identify, classify, work up, and treat these disorders.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!